KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Change in Account Payables (2016 - 2022)

Historic Change in Account Payables for Inovio Pharmaceuticals (INO) over the last 14 years, with Q1 2022 value amounting to $859354.0.

  • Inovio Pharmaceuticals' Change in Account Payables rose 58588.1% to $859354.0 in Q1 2022 from the same period last year, while for Mar 2022 it was $639125.0, marking a year-over-year decrease of 1211.33%. This contributed to the annual value of -$94937.0 for FY2021, which is 16998.67% down from last year.
  • According to the latest figures from Q1 2022, Inovio Pharmaceuticals' Change in Account Payables is $859354.0, which was up 58588.1% from $56387.0 recorded in Q4 2021.
  • In the past 5 years, Inovio Pharmaceuticals' Change in Account Payables registered a high of $1.0 million during Q2 2021, and its lowest value of -$1.3 million during Q3 2021.
  • Over the past 5 years, Inovio Pharmaceuticals' median Change in Account Payables value was $125292.0 (recorded in 2021), while the average stood at $41344.3.
  • In the last 5 years, Inovio Pharmaceuticals' Change in Account Payables plummeted by 55311.46% in 2021 and then skyrocketed by 58588.1% in 2022.
  • Over the past 5 years, Inovio Pharmaceuticals' Change in Account Payables (Quarter) stood at $286872.0 in 2018, then decreased by 6.88% to $267133.0 in 2019, then tumbled by 156.89% to -$151959.0 in 2020, then skyrocketed by 137.11% to $56387.0 in 2021, then skyrocketed by 1424.03% to $859354.0 in 2022.
  • Its Change in Account Payables stands at $859354.0 for Q1 2022, versus $56387.0 for Q4 2021 and -$1.3 million for Q3 2021.